Core--National Cell Procuremen

国家造血祖细胞处理核心的具体目标与之前PEGT赠款期间的目标相似，为NIH资助的研究人员提供大量丰富的人类造血干细胞或其他细胞群，以促进他们的基础研究和临床前研究。核心将通过首先采购足够数量的初始材料来实现这一点，以便进行大规模加工和细胞选择。该中心实施捐献者招募计划，从正常志愿者那里获取G-CSF动员的和非动员的采集，还从西北组织中心和国家疾病研究交换中心获得身体骨髓。核心处理这些收集以获得大量丰富的细胞子集，提供的选择类型包括CD34， CD14、CD19、CD22、CDS、CD4或CDS。Core通过三色或四色流式细胞术对这些细胞进行表征，冷冻保存等量的细胞以供长期储存，并将组件运送给提出请求的研究人员。在之前的PEGT期间，Core对CD34进行了80多次大规模浓缩，平均最终纯度为90%，收益率为60%。还进行了CD14(n=40)和T细胞(n=20)的额外选择，最终纯度和得率更高。Core已经向来自30多个机构的60多名不同调查人员分发了3500多瓶浓缩细胞，与商业供应商相比，成本大大降低。总而言之，该中心将继续为美国国立卫生研究院资助的研究提供独特和关键的服务，为研究人员提供大量丰富的细胞群体 体外实验、动物模型试验和临床前评估。

The specific aims of the National Hematopoietic Progenitor Cell Processing Core remain similar to those from the previous PEGT grant period, to provide NIH-funded investigators with large numbers of enriched human hematopoietic stem cells or other cell populations to facilitate their basic research and pre-clinical studies. The Core will accomplish this by first procuring sufficient amounts of starting material for large-scale processing and cell selection. The Core operates a donor recruitment program to obtain G-CSF mobilized and non-mobilized collections from normal volunteers, and also obtains cadaveric bone marrow from the Northwest Tissue Center and National Disease Research Interchange. The Core processes these collections to obtain large numbers of enriched cell subsets, the types of selections offered include CD34, CD14, CD19, CD22, CDS, CD4, or CDS. The Core characterizes these cells by 3 or 4-color flow cytometry, cryopreserves aliquots for long-term storage, and ships components to requesting investigators. During the previous PEGT the Core performed over 80 large-scale enrichments for CD34, with average final purities >90% and yields of 60%. Additional selections for CD14 (n=40) and T-cells (n=20) have also been performed, with even higher final purities and yields. The Core has distributed over 3,500 vials of enriched cells to more than 60 different investigators from more than 30 institutions, at a greatly reduced cost relative to commercial suppliers. In summary, this Core will continue to provide a unique and critical service in support of NIH funded research, supplying investigators with large numbers of enriched cell populations for in vitro experimentation, animal model testing, and pre-clinical evaluations.